Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis.
暂无分享,去创建一个
C. Di Mario | I. Olivotto | A. Tomberli | N. Marchionni | A. Ungar | F. Perfetto | M. Zampieri | C. Fumagalli | F. Cappelli | L. Tassetti | B. Tomberli | K. Baldini | C. Zocchi | N. Maurizi | G. Nardi | M. Gabriele | G. Del Monaco | Guido Del Monaco
[1] C. Rapezzi,et al. A new therapy for transthyretin amyloidosis, no longer an orphan condition , 2020, European heart journal supplements : journal of the European Society of Cardiology.
[2] H. Vase,et al. Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge. , 2020, International journal of cardiology.
[3] J. Gurwitz,et al. Tafamidis-A Pricey Therapy for a Not-So-Rare Condition. , 2020, JAMA cardiology.
[4] G. Parati,et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. , 2020, International journal of cardiology.
[5] M. Emdin,et al. Treatment of cardiac transthyretin amyloidosis: an update. , 2019, European heart journal.
[6] C. Rapezzi,et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. , 2019, Circulation. Heart failure.
[7] A. Petrie,et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. , 2019, Circulation.
[8] F. Domínguez,et al. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[9] M. Maurer,et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.
[10] F. Dominici,et al. Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. , 2019, Circulation. Heart failure.
[11] P. Kyriakou,et al. Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers , 2018, BMC Cardiovascular Disorders.
[12] Sanjiv J. Shah,et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.
[13] A. Petrie,et al. A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.
[14] M. Halushka,et al. Seven factors predict a delayed diagnosis of cardiac amyloidosis , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[15] C. Rapezzi,et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.
[16] James C Moon,et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.
[17] F. Salvi,et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.
[18] R A Kyle,et al. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. , 1983, The American journal of medicine.